Alpha-glucosidase Inhibitors Market Outlook:
Alpha-glucosidase Inhibitors Market size was valued at USD 4.46 billion in 2025 and is expected to reach USD 5.82 billion by 2035, expanding at around 2.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of alpha-glucosidase inhibitors is evaluated at USD 4.57 billion.
One of the major factors boosting the alpha-glucosidase inhibitors market is the increasing prevalence of diabetes across the world. For instance, according to a 2023 published report by the Institute for Health Metrics and Evaluation (IHME), , states that more than half a billion people are living with diabetes around the globe. The worldwide prevalence rate of diabetes is 6.1%, whereas North America and the Middle East hold 9.3% and is predicted to reach 16.8% by 2050. Furthermore, based on demographics, people 65 and older age are capturing more than 20% of the diabetes prevalence rate. The rising risk of diabetes drives demand for effective glucose management therapies and is generating profitable opportunities for anti-diabetic drug producers. Moreover, the key market players are investing heavily in research and development activities to introduce advanced and effective solutions such as alpha-glucosidase inhibitors.
